← Back to Clinical Trials
Recruiting NCT07060261

NCT07060261 Pre-Op MRI on Margin Status for Transoral Robotic Surgery for HPV+ Tonsillar Squamous Cell Carcinoma

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07060261
Status Recruiting
Phase
Sponsor Case Comprehensive Cancer Center
Condition Human Papilloma Virus Related Carcinoma
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2025-11-26
Primary Completion 2026-09

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Transoral robotic surgery+MRI

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2025-11-26 with a primary completion date of 2026-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This prospective research study aims to see if pre-operative MRI can predict the margin status after transoral robotic surgery (TORS) for human papillomavirus positive (HPV+) tonsillar squamous cell carcinoma (SCC). The pre-operative MRI will have a standard MR neck without and with contrast, with added axial T2 weighted sequence and T2 SPACE sequence through the tonsils. Three neuroradiologists will grade the thickness of the pharyngeal constrictor muscle (the muscle that surrounds the tonsils) on a five-point scale. The study will determine if the pre-operative MRI grading will correlate with positive, insecure (\<1mm), or secure (\>1mm) margin during TORS surgery for your HPV+ tonsillar SCC.

Eligibility Criteria

Inclusion Criteria: 1. Adults ≥ 18 years of age. 2. Participants being considered for TORS for HPV+ tonsillar SCC. Exclusion Criteria: 1. Participants \< 18 years of age. 2. Participants who cannot provide informed consent. 3. Participants who do not wish to participate. 4. Vulnerable populations, including but not limited to cognitively impaired persons, pregnant women, and students or house staff under the direct supervision of the investigator. 5. Participants in whom MRI is contraindicated.

Contact & Investigator

Central Contact

Jonathan Lee, MD

✉ LEEJ13@ccf.org

📞 216-445-9390

Frequently Asked Questions

Who can join the NCT07060261 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Human Papilloma Virus Related Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07060261 currently recruiting?

Yes, NCT07060261 is actively recruiting participants. Contact the research team at LEEJ13@ccf.org for enrollment information.

Where is the NCT07060261 trial being conducted?

This trial is being conducted at Cleveland, United States.

Who is sponsoring the NCT07060261 clinical trial?

NCT07060261 is sponsored by Case Comprehensive Cancer Center. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology